Last reviewed · How we verify
NCT05690880
ForeseeHome NRich Registry
trial testing Foresee Home in Age-Related Macular Degeneration in 20,000 participants. Participants enrolled and being followed up; not accepting new ones.
15 December 2027
Quick facts
| Lead sponsor | Notal Vision Inc. |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 20,000 |
| Start date | 15 December 2022 |
| Primary completion | 15 December 2027 |
| Estimated completion | 15 December 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Foresee Home
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
Sponsor
Notal Vision Inc.
Who can join
Eligibility, any sex, with Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This registry will compare functional and structural data of progression of Intermediate AMD (iAMD) and conversion to neovascular AMD (NV-AMD) while monitored at home with the ForeseeHome Monitoring System (FSH) and during routine care with Spectral Domain Optical Coherence Tomography (SD-OCT) and to validate the predictive value of a non-NV-AMD FSH alerts.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05690880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other Notal Vision Inc. trials
Trials by the same sponsor.
- NCT05745116 — Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT · unknown
- NCT05650047 — Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD · unknown
- NCT05417152 — Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients · completed
- NCT05202587 — The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT · completed
- NCT05281042 — Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05690880 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Notal Vision Inc.
- Last refreshed: 15 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05690880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing